Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Imunon Inc (IMNN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.90-0.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMNN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain active capital allocation and financing | A primary condition in Imunon Inc's published investment case. The stated target is Register at least $7M common stock and issue 250 preferred shares. | Intact | Fails to raise or register $7M common stock or issue 250 preferred shares by 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, clinical-stage biotechnology company, not an established earnings compounder. Its multi-year view is in a watch state: OVATION 3 is progressing, while financial performance remains below its industry cohort.
The valuation model shows a durable premium to peers, while its expectations gap is negative, suggesting expectations are demanding relative to the evidence. The priced-in signal is tagged justified, with low fragility, but confidence in the valuation model is medium.
Near term, IMNN is likely to remain loss-making while it advances OVATION 3; the supplied evidence shows no revenue. Enrollment has exceeded management’s forecast, but reported operating expenses have not declined, and first-half cash use was higher than in the prior-year period. The expected financing is intended to support enrollment, while the company’s high risk and volatile management add uncertainty.
Over the next one to three years, the thesis hinges on continued trial progress and whether management can contain expenses and support enrollment with available financing. Near term, weakening jobs data could increase pressure on cyclical and healthcare names, while continued strength from sector bellwethers could sustain a sector tailwind; misses or weaker guidance from those companies could weaken it.
IMNN offers a high-risk, trial-driven multi-year view with operational progress but no demonstrated revenue and limited evidence of expense control. The central question is whether trial execution and financing can strengthen the business fundamentals. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage executive leadership transitions smoothly |
| A supporting condition in Imunon Inc's published investment case. The stated target is Complete leadership transitions with minimal disruption. |
| Intact |
| Leadership changes cause major disruption or resignations in next 4 quarters |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Control operating losses and improve cash flow | A primary condition in Imunon Inc's published investment case. The stated target is Reduce operating losses to no worse than -$4.3M and cash flow to no worse than -$4.0M. | Broken | Operating losses or cash flow worsen beyond -$4.3M and -$4.0M respectively next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance Phase 3 ovarian cancer study | Imunon is advancing a key Phase 3 cancer study with $10M funding. | Intact | Phase 3 study delays or funding withdrawal in next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.15 → $-1.82 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-07-25 | $-2.18 | $0 | 4 / 4 |
| 2026-07-26 | $-2.18 | $0 | 4 / 4 |
| 2026-07-27 | $-2.18 | $0 | 4 / 4 |
| 2026-07-28 | $-2.18 | $0 | 4 / 4 |
| 2026-07-29 | $-2.18 | $0 | 4 / 4 |
| 2026-07-30 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-07-31 | $-2.18 | $0 | 4 / 4 |
| 2026-08-01 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-02 | $-2.18 | $0 | 4 / 4 |
| 2026-08-03 | $-2.18 | $0 | 4 / 4 |
| 2026-08-04 | $-2.18 | $0 | 4 / 4 |
| 2026-08-05 | $-2.18 | $0 | 4 / 4 |
| 2026-08-06 | $-2.18 | $0 | 4 / 4 |
| 2026-08-07 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-08 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-09 | $-2.18 | $0 | 4 / 4 |
| 2026-08-10 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-12 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-13 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-14 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-15 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-16 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-17 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-18 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-19 | $-2.15 | $5,425,000 | 3 / 4 |
| 2026-08-20 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-21 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-22 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-23 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-24 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-25 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-26 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-27 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-28 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-29 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-30 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-08-31 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-01 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-02 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-03 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-04 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-05 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-06 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-07 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-08 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-09 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-10 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-11 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-12 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-13 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-14 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-15 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-16 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-17 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-18 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-19 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-20 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-21 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-22 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-23 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-24 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-25 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-26 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-27 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-28 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-29 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-09-30 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-01 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-02 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-03 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-04 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-05 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-06 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-07 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-08 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-09 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-10 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-11 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-12 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-13 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-14 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-15 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-16 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-17 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-18 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-19 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-20 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-21 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-22 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-23 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-24 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-25 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-26 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-27 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-28 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-29 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-30 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-10-31 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-11-01 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-11-02 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-11-03 | $-1.82 | $5,425,000 | 3 / 4 |
| 2026-11-04 | $-1.82 | $5,425,000 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.